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Abstract
This paper shows how metabolic control analysis (MCA) can help to explain two important features of mitochondrial
diseases: (i) the existence of a threshold in the expression of the complex deficiencies on the respiratory flux or on ATP
synthesis, i.e. the fact that it is necessary to have a large complex deficiency in order to observe a substantial decrease in these
fluxes; (ii) the tissue specificity, i.e. the fact that all tissues are not affected, even if the complex deficiency is present in all of
them. We also show the limits of MCA, particularly when considering the in vivo situation. However, MCA offers a new way
to consider mitochondrial diseases. The fact that fluxes only slightly change, when a complex is affected, is done at the
expense of great changes in intermediate metabolite concentrations; intermediate metabolites situated upstream from the
deficient complex are more reduced, leading to a greater generation of free radicals. This could bring an explanation for the
diseases observed in conditions where the mitochondrial rate of ATP synthesis is only slightly affected. ß 2001 Elsevier
Science B.V. All rights reserved.
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1. Introduction
One of the ¢rst paradoxes, which early appeared in
the study of mitochondrial diseases, is that several
unrelated tissues can be a¡ected, leading to an un-
expected association of neuromuscular and/or non-
neuromuscular symptoms (mitochondrial myopathy,
peripheral neuropathy, encephalopathy and gastroin-
testinal diseases (MNGIE), neurogenic muscle weak-
ness, ataxia, retinitis pigmentosa (NARP), diabetes
and deafness...) [1^5]. This is well understandable
when taking into account the simple fact that nearly
all tissues contain mitochondria. However, such an
argumentation should lead to the obvious conclusion
that all tissues should be a¡ected. This apparent con-
tradiction emphasizes several well-known, but often
forgotten properties of mitochondria.
First, mitochondria play di¡erent roles in cell
physiology not only to supply energy to the cell
but also to maintain the redox potential, to store
an appreciable amount of calcium [6^8], to modulate
calcium signals [9^11], to produce heat [12] and free
radicals [13], to introduce cells in apoptosis
[11,14,15], etc. A mutation can more or less a¡ect
one or the other of these functions and thus at the
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same time the tissues which depend on it. Second, the
diversity of mitochondria themselves, already ob-
vious in electronic microscopy observations [16] : liv-
er mitochondria di¡er from heart mitochondria
which are di¡erent from muscle and brain mitochon-
dria. Mitochondria from some other tissues are still
more speci¢c (adipose tissues, spermatozoon) [16].
Thus it is di⁄cult to admit, although not impossible,
that all types of mitochondria in di¡erent tissues uni-
formly perform the same function of ATP produc-
tion.
Third, the dual origin of the oxidative phosphor-
ylation complex subunits, encoded by nuclear or mi-
tochondrial DNA (mtDNA). This implies a complex
regulation of nuclear vs. mitochondrial gene expres-
sion (gene dosage), which, although out of the scope
of this paper, has to be kept in mind. This leads to
the fourth point, the particularities of mitochondrial
genetics, i.e. the nearly complete maternal inheritance
of mtDNA and the important concept of hetero-
plasmy of mtDNA mutations (Fig. 1): most of the
cells contain hundreds of mitochondria, each con-
taining two to ten mitochondrial DNA; it means
that each cell contains thousands of mtDNA, i.e.
thousands of copies of the genes coding for the
mtDNA encoded subunits of oxidative phosphoryla-
tion complexes (in comparison to only two copies of
the nuclear DNA encoded subunits of the same com-
plexes!). When there is a mtDNA mutation, not all
the mtDNA molecules necessarily carry the muta-
tion, so that a mixture of mutated and wild-type
mtDNA coexists in the same cell, or even in the
same mitochondria. The heteroplasmy is de¢ned as
the percentage of mutated mtDNA over the total
mtDNA molecules. Due to the great number of
mtDNA molecules in a cell, heteroplasmy of mtDNA
mutations can vary, quasi-continuously, between 0
(no mutation, normal situation, also called homo-
plasmy) to 100%. Heteroplasmy is not necessarily
the same in all cells, in all tissues and in all the
members of the same family. The heteroplasmy,
with its large natural variations, often in the same
patient, has immediately formulated the question of
the expression of mtDNA mutations in quantitative
terms, thus logically leading to consider metabolic
control analysis (MCA) as an appropriate tool.
This led to the emergence of another concept, the
concept of threshold in the expression of mitochon-
drial defects as a function of the intensity of the
defect.
1.1. The threshold in the expression of mtDNA
mutations
It rapidly appeared that the expression of a
mtDNA mutation is not proportional to its degree
of heteroplasmy, i.e. that it is necessary to have a
high degree of heteroplasmy (sometimes more than
90%) in order to observe the clinical signs of the
pathology. Low levels of heteroplasmy in any tissue
or more generally in a subject give no sign of disease.
This is also true at the level of individual cells [17]. In
1986, D.C. Wallace already described this phenom-
enon for a mutation located in the mitochondrial 16S
RNA coding gene and conferring chloramphenicol
resistance [2,18]. Indeed, human hybrids with less
than 10% of mutated mtDNA were killed in the
presence of chloramphenicol whereas hybrids with
12% mutated mtDNA could grow in the presence
of the drug.
In MERRF (myoclonic epilepsy with ragged red
¢bers) patients, the complete range of phenotypic
and biochemical variation from normal to severely
a¡ected was found in individuals carrying between
27% and 2% wild-type mtDNA coexisting with mu-
tated mtDNA [19]. In this case, a small percentage of
Fig. 1. Heteroplasmy of mutant mtDNA. Di¡erent cells (large
circle) with di¡erent percentages of mutant mtDNA (small bold
circles) in their mitochondria (intermediate circles). The nucleus
is not represented. Note the di¡erence in the two cases of hetero-
plasmy: in (b), all mitochondria contain wild-type and mutant
mtDNA; in (c) mitochondria contain only one type of mtDNA,
either wild-type or mutant.
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normal mtDNA appears to be enough to maintain a
normal phenotype. The same observation was re-
ported by Attardi’s group on cell lines in the case
of MELAS (mitochondrial encephalopathy, lactic
acidosis and stroke-like episodes) 3243 mutation
[20,21]; they evidenced a threshold in heteroplasmy
around 90%, before which the respiratory rate was
completely normal and after which it decreased very
rapidly. In other words, 10% of wild-type mtDNA
were su⁄cient to sustain a normal respiratory rate.
In [22] Porteous et al. constructed a series of cy-
brids containing 0^86% of a CPEO (chronic progres-
sive external ophthalmoplegia) patient with the 4977
bp common deletion (vmtDNA). In cybrids contain-
ing less than 50^55% of vmtDNA, the mitochondrial
potential, the rate of ATP synthesis and the ATP/
ADP ratio were the same as in the cybrids with in-
tact mtDNA. However, once the proportion of
vmtDNA exceeded this threshold, these bioenergetic
parameters decreased.
The question thus arises of the mechanism of this
threshold expression.
Fig. 2 depicts all the steps leading from the genes
encoding a complex to the £ux of respiration and of
ATP synthesis. At each step a compensatory mecha-
nism could occur explaining that the phenotypic ex-
pression does not linearly follow the degree of hetero-
plasmy. To locate the relevant step(s), it is necessary
to measure, for a given degree of heteroplasmy, the
amount of normal mRNA, possibly of tRNA and
rRNA, the amount of each complex, its activity
and the global £uxes of oxygen consumption and
ATP synthesis. Few studies are available with the
simultaneous measurements of all these parameters.
One of them comes from the laboratory of Serge
Alziari in Clermont-Ferrand [23,24] and concerns a
deletion in the mitochondrial DNA of a Drosophila
species. The results exhibit a slight elevation of the
wild-type compounds at each step of the process:
although the percentage of wild-type mtDNA is
only 30% of total mtDNA, the percentage of a
mRNA corresponding to genes involved in the dele-
tion ranges from to 35 to 55% of the corresponding
normal mRNA content. The activities of complexes I
and III, some subunits of which are involved in the
deletion, are 60% and 70% respectively of the normal
activity. Finally, this ends up with a quasi-normal
recovery of the respiratory £ux (for a complete anal-
ysis of this case see [25]).
Another report comes from the laboratory of van
den Bogert in Amsterdam [26] in the case of a Pear-
son syndrome, and essentially shows the same pat-
tern: 40% of mtDNA deletion, an amount of 40 and
50% of two mRNAs involved in the deletion com-
pared to the normal level of these mRNAs, 81^88%
of cytochrome c oxidase activity and a normal rate
of ATP synthesis.
More recently [27], Bai et al. showed that in a
series of mouse cell lines carrying a nonsense
mtDNA mutation for the ND5 subunit containing
between 4 and 100% of the normal number of
wild-type ND5 genes, the functional mRNA level
Fig. 2. Expression of mtDNA and nuclear mutations in mitochondria.
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was decreased in proportion to the number of wild-
type ND5 genes; however, cells carrying 60% of
wild-type mRNA were capable of carrying out a
normal rate of translation indicating that 40% of
ND5 mRNA is in excess.
In a very interesting paper, Heddi et al. [28] show
that in a case of a MELAS patient, the analysis of
transcripts in several tissues shows a strong increase
only when the percentage of mutant mtDNA is 90%
or more. This increase not only concerns the mito-
chondrial transcript but also some nuclear transcripts
such as the ones of ATP synthase L subunit, the
heart muscle isoform of the adenine nucleotide trans-
locator, muscle mitochondrial creatine kinase, muscle
glycogen phosphorylase, hexokinase I, muscle phos-
phofructokinase, the E1K subunit of pyruvate dehy-
drogenase and the ubiquinone oxidoreductase. In
this patient’s kidney, the percentage of mutant
mtDNA is only 73% and the amount of messenger
RNA is similar to that of the controls. The transcript
levels in another MELAS patient with 50% mutant
mtDNAs and in a MERRF patient with 78% mutant
mtDNAs were not particularly elevated. These few
reports, and particularly the last one, seem to indi-
cate that until a large threshold in mutant mtDNA
heteroplasmy (70%) ^ a threshold until which the
respiratory £ux and the ATP synthesis are weakly
a¡ected ^ the increase of the normal mitochondrial
transcripts is not particularly elevated (if any). Thus
the main compensatory mechanism responsible for
the maintenance of the £uxes has to be searched
probably after these steps, in the oxidative phosphor-
ylation network itself.
1.2. The threshold in the expression of complex
de¢ciencies
It is rather easy to mimic the e¡ects of oxidative
phosphorylation complex de¢ciencies because speci¢c
inhibitors are known for all of them. In other words,
it is thus possible to observe the e¡ects on respiration
or on ATP synthesis of a modulation of respiratory
chain complex activities induced by speci¢c inhibi-
tors. So we did for all the di¡erent complexes of
respiratory chain in rat muscle mitochondria
[29,30]. Fig. 3 shows the e¡ect of cyanide inhibition
on cytochrome c oxidase activity alone and on the
respiration. It can be seen that even at 50% cyto-
chrome c oxidase inhibition one only observes a
very weak inhibition of the whole £ux and one has
to go as far as 80^90% inhibition of the isolated step
in order to obtain a substantial inhibition of the
respiration. This is more obvious on the representa-
tion in Fig. 3B, called ‘threshold plot’, where we have
plotted the percentage of the respiratory £ux as a
function of the cytochrome c oxidase inhibition for
the same cyanide concentrations. What we observe is
a clear-cut threshold: until 70% inhibition of cyto-
chrome c oxidase activity the respiratory rate de-
creases slowly and linearly, but beyond 70% of cyto-
chrome c oxidase inhibition the respiratory rate
abruptly falls to reach the zero level.
A similar pattern is observed for all the oxidative
phosphorylation complexes [31,32].
This behavior is clearly explained in the frame-
work of the metabolic control theory [33^35]. The
ratio of the initial slopes of the two curves of Fig.
3A measures the control coe⁄cient of cytochrome c
oxidase on oxygen consumption £ux; this control
coe⁄cient is also measured by the initial slope at
the ‘threshold curve’ of Fig. 3B (the control coe⁄-
cient is de¢ned as the change in the £ux divided by
the causal change in the step; these changes are re-
£ected in the initial slopes to the inhibition curves in
Fig. 3A; the control coe⁄cient is also exactly the
initial slope to the threshold curve in Fig. 3B). Be-
cause most of the control coe⁄cients are found ex-
perimentally small (of the order of 0.1^0.2 in the case
of muscle [29], presumably partly due to the summa-
tion theorem), such threshold curves with an initial
plateau are inescapable: we must have (see Fig. 3), at
the beginning, a weak slope due to the low control
coe⁄cient. On the contrary, at a very low activity of
the step both curves must meet again, due to the fact
that the £ux becomes zero when the step is being
inactivated. This unavoidably leads to a sigmoid in-
hibition shape of the £ux inhibition curve and to a
threshold e¡ect when the £ux is plotted as a function
of the inhibition of one of its steps.
This behavior has already been observed for the
cytochrome c oxidase activity (COX activity). For
instance, Bindo¡ and Turnbull in Newcastle [36] ob-
served that both in a patient with cytochrome c ox-
idase de¢ciency and in an animal model, a copper-
de¢cient rat, lowering the activity of complex IV by
over 50% did not a¡ect the respiratory £ux. More
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recently, Kuznetsov and Kunz [37] showed that, in a
mouse mutant with a severe copper de¢ciency, the
activity of COX is only about one half of the normal
activity, but that no di¡erence was found in maximal
rates of respiration; however, the control coe⁄cient
was higher in the mutants (0.8 instead of 0.30 for the
control value), indicating a greater sensitivity to any
variation.
Davey and Clark [38] also evidenced a distribution
between several steps of the control of oxidative
phosphorylation in non-synaptic rat brain mitochon-
dria. They found a control coe⁄cient of 0.14 for
complex I, of 0.15 for complex III and of 0.24 for
complex IV. More interestingly, they drew the
‘threshold curves’ and found high threshold values
of 72%, 70% and 60% respectively. In a further
work [39,40] they compared the control of non-syn-
aptic and synaptic rat brain mitochondria and re-
ported big changes in the activities, control and
threshold. When passing from non-synaptosomal to
synaptosomal mitochondria, the activity of complex
I (scaled by citrate synthase activity) is reduced by a
factor of 1.2. On the contrary, complex IV activity
(also scaled by citrate synthase activity) is increased
by a factor of 2. They observed, as expected, a strong
increase of the £ux control coe⁄cient of complex I
(from 0.13 to 0.30) and a decrease of complex IV
control coe⁄cient (from 0.20 to 0.15). A very low
threshold (25%) is associated to the higher control
coe⁄cient of complex I in synaptosomal mitochon-
dria, suggesting that even for weak decrease of com-
plex I activity energy metabolism should be severely
impaired [40,41].
It should be pointed out that this study of a bio-
chemical threshold applies equally well to mitochon-
drial mutations and to nuclear ones; it only takes
into account the defect in a given complex and not
the origin of the defect itself.
1.3. Tissue speci¢city in the control of oxidative
phosphorylation
These studies emphasize one of the important con-
sequences of the summation theorem in metabolic
control theory, namely the fact that the distribution
of the control of a pathway among its di¡erent steps
can vary according to several factors and more par-
ticularly to the steady state, the tissue and the com-
parative amount of the di¡erent activities involved in
the pathway. All these three factors can vary when
comparing di¡erent tissues. That is the reason why
we undertook a systematic study of the control co-
e⁄cients and the associated threshold of seven steps
of oxidative phosphorylation in ¢ve tissues: muscle,
heart, brain, liver and kidney [31,32]. We evidenced
two tissue groups, each characterized by similar
threshold values: the muscle and the heart on the
one hand, which are more controlled by the respira-
tory chain, and the kidney and the brain on the other
hand which are more controlled by the ATP synthe-
sis machinery (ATP synthase, Pi carrier and ATP/
ADP translocator). The liver can be associated to
Fig. 3. (A) KCN inhibition of respiratory rate (F) with 10 mM pyruvate+10 mM malate as respiratory substrate and of cytochrome c
oxidase activity using ascorbate/TMPD as substrate (E) in the presence of 2 mM ADP. (B) Respiratory rate as a function of cyto-
chrome c oxidase inhibition. The points are the means of the data of panel A, corresponding to the same KCN concentrations. (Re-
produced with permission from the authors, Biochemical Journal 302 (1994) 171^174. Copyright holder: the Biochemical Society [30].)
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either one or the other of these two groups according
to the complex. A correlation can be obtained when
plotting the threshold value as a function of the cor-
responding control coe⁄cient for the same complex
in the same tissue. Although there is no mathemat-
ical reason for such a correlation, it is not unex-
pected that the lower the control coe⁄cient, the
greater the threshold value. However, it can be
seen that di¡erent threshold values can be associated
with the same control coe⁄cient; this is due to the
fact that control coe⁄cients are de¢ned locally in the
linear neighbourhood of the initial steady state, while
threshold values correspond to bigger changes (Fig.
4).
We observed that the threshold curves can present
two kinds of shape, which we called type I and type
II [31]. Type I curves are characterized by a large
plateau associated with a great threshold value. In
type II curves, a plateau is no longer apparent and
a threshold is hardly de¢ned. The plateau of type I
curves is due to an excess of enzyme capacity which
has to be suppressed before an e¡ect on the £ux
would be appreciable. In type II curves, the enzyme
reserve is small and the curve only re£ects the adjust-
ment of the metabolites inside the network which
bu¡er the changes in the complex activity. As a mat-
ter of fact, type II curves correspond to the last part
of type I curves beginning just before the threshold
point (Fig. 5).
The variation in biochemical threshold values for a
given complex according to the tissue origin of the
mitochondria suggests an explanation (among
others) of the tissue speci¢city observed in mitochon-
drial cytopathies. For a given oxidative phosphory-
lating complex, the lower the threshold value in a
tissue, the more sensitive this tissue to a defect of
this complex. For example, we showed [31] that an
80% decrease in cytochrome c oxidase activity will
induce a small decrease in mitochondrial respiration
in liver, while the respiration will be decreased to
40% in heart mitochondria. This work also shows
that it is possible to pass from one type of threshold
curve to the other for the same complex (here the
ATP/ADP translocator in liver) depending upon
the respiratory substrate (pyruvate or succinate).
This has an obvious application to mitochondrial
diseases because di¡erent tissues do not use prefer-
entially the same respiratory substrate (pyruvate,
fatty acids, ketone bodies, etc.) and thus for the rea-
son stated above will not be a¡ected by the same
defect to the same extent. This adds another reason
to observe tissue speci¢city in mitochondrial diseases.
It must be noted that most of the threshold values
are high (s 50%). This phenomenon could be a way
to provide a safety margin for oxidative phosphory-
lation against a defect in one or several of its com-
plexes. This observation can be correlated with the
fact that in most patients with clinical features of
mitochondrial cytopathies of mtDNA mutation ori-
Fig. 5. Threshold curves of types I and II.
Fig. 4. Threshold values as a function of control coe⁄cient
values. The data are taken from [31] and [32]. 8, complex I;
b, complex III; 7, complex IV; F, ATPase; E, ATP/ADP
translocator; R, Pi carrier. The correlation coe⁄cient is 0.90.
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gin, the proportion of mutant mitochondrial DNA
has to be rather high in order to observe a pheno-
typic e¡ect.
1.4. The control of oxidative phosphorylation in whole
cells
Villani and Attardi [42,43] analyzed the control of
respiration by cytochrome c oxidase in intact cul-
tured human osteosarcoma 143B.TK3 cells, the hep-
atoma HepG2 cell line, lung carcinoma A-549, the
neuroblastoma SK-N-SH cell line, the SKO-007 (J3)
myeloma cell line and in mitochondrial DNA muta-
tion-carrying human cell lines. They compared the
uncoupled endogenous respiration of the whole chain
to the respiration of cytochrome c oxidase isolated
from the rest of the chain with antimycin and fed
with ascorbate and TMPD (N,N,NP,NP-tetramethyl-
p-phenylenediamine). Surprisingly they found low
threshold values (20% or less) in all types of normal
cell lines, especially in the 143B.TK3, indicating that
cytochrome c oxidase capacity could be in low excess
in intact cells and thus exert a tighter control on
oxidative phosphorylation than could be assumed
on the basis of experiments carried out on isolated
mitochondria. They con¢rm these results on digito-
nin-permeabilized cells respiring on glutamate/ma-
late.
Wisniewski et al. [44] studied the control of oxida-
tive phosphorylation on saponin-skinned ¢bers. They
stimulated state 3 respiration with calcium which ac-
tivates actomyosin ATPases. In these conditions they
found control coe⁄cient values of 0.16 for mitochon-
drial ATP synthase, 0.34 for adenine nucleotide
translocase, 0.08 for phosphate carrier, 0.01 for com-
plex I and 0.09 for cytochrome c oxidase. The inhi-
bition of cytochrome c oxidase itself by KCN (Fig. 7
in their paper) evidenced a strong sigmoicity with a
large plateau and was very similar to the inhibition
of respiration by KCN of isolated muscle mitochon-
dria in Fig. 3A. One can infer from this curve a
similar threshold value for the corresponding thresh-
old curve. It means that in these experiments, mito-
chondria in permeabilized ¢bers do not behave dif-
ferently from isolated mitochondria.
The discrepancy between the results reported by
the group of Attardi and the group of Kunz [44]
may have di¡erent reasons. First, the material on
which they work is very di¡erent. Attardi’s group
mainly works with tumor cells, which are probably
more glycolytic than aerobic; they may have a per-
turbated oxidative metabolism with particularly low
levels of some of the respiratory chain complexes.
Second, they stimulate respiration by uncoupling,
unlike Kunz’s group who stimulates the respiration
of their permeabilized ¢bers by the demand in in-
creasing ATP turnover with actomyosin ATPase ac-
tivity. This is probably a more physiological situa-
tion; it can certainly be thought that, in these
conditions, the demand in ATP is a strongly control-
ling step and indeed, Wisniewski et al. measured a
control coe⁄cient of 0.5 for actomyosin ATPase.
Third, one cannot exclude that in permeabilized ¢-
bers the organization of the cytoskeleton or the bind-
ing of mitochondria to the cytoskeleton has been
perturbed so that the control in the permeabilized
¢bers resembles more that of isolated mitochondria
and is not representative of the physiological situa-
tion; however, all the data on permeabilized ¢bers,
including electron microscopy [45,46] and the di¡er-
ent accessibility of ADP and other substrates for
mitochondria [47,48], do not favor this hypothesis.
Barrientos and Moraes [49] used a drug-induced
model (rotenone-dependent complex I inhibition in
a human osteosarcoma-derived cell line) and a genet-
ic model of human xenomitochondrial cybrids (HCX
lines) to quantify the physiological consequences of a
partial inhibition of complex I. At 1 nM rotenone
incubation for 4 h in the cell culture medium, they
observed a 19% complex I inhibition but still 98% of
cell respiration rate. Only when complex I was inhib-
ited by 35^40%, cell respiration began to decrease.
HXC have an approx. 40% complex I inhibition and
an approx. 80% residual cell respiration. This indi-
cates a comparable control of complex I in whole
cells and in isolated mitochondria.
2. Conclusion
2.1. The control of oxidative phosphorylation in
isolated mitochondria
Although MCA does certainly not explain all the
particular features of the expression of mutations
a¡ecting mitochondria, and perhaps does not satisfy
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all the criteria in order to be applied to oxidative
phosphorylation (see below), it, however, gives a
framework in which these features can be logically
accommodated or at least discussed and even in
some cases rejected. The analysis of the expression
of the de¢ciencies a¡ecting mitochondria in the light
of MCA allowed to understand several, at ¢rst sight
paradoxical, properties.
The fact that in many cases there is not a linear
correspondence between the degree of the de¢ciency
and the decrease in the £uxes, particularly the £ux of
ATP synthesis. MCA explains particularly well the
concept of threshold which is now well recognized in
the expression of complex de¢ciencies, in relationship
with the concept of control coe⁄cients, although the
two concepts are not identical. This concept of
threshold is general in the metabolism as stressed
by Kacser and Burns [50].
Because in MCA the dependence of the control
coe⁄cients on the steady state and on the elasticities
of the di¡erent steps of a metabolic network has al-
ways been emphasized, it prompted us to recognize
that the functional and structural di¡erences in the
mitochondria from various tissues or organisms can
modulate the value of the thresholds; this is an ex-
planation (certainly not the only one) of the observed
tissue variation in the expression of mutations a¡ect-
ing mitochondria.
This situation is certainly not speci¢c to mitochon-
dria. A long time ago, it was described by Kacser
and Burns [50] on a variety of systems; they have
explained in this way the apparent evolutionary par-
adox of the heterozygote, carrying roughly half of
the normal activity of the wild-type homozygote
and nevertheless maintaining normal £uxes and
they conclude that in the metabolism it cannot be
avoided that most of the enzymes appear, each, as
if they were in excess.
Note that, in mitochondria, the steady state can-
not only change in response to the ATP demand (or
in response to other functions) in the cell, but also in
response to changes in the respiratory substrate used
(or the combination of respiratory substrate (see the
paper of Kunz in this issue)).
2.2. Control of oxidative phosphorylation in vivo
One can wonder whether the distribution of the
control and the large enzymatic reserves observed
in isolated mitochondria can be applied to the in
vivo situation. If metabolic control analysis applies
to the in vivo situation one can predict that the con-
trol values and the threshold may have di¡erent val-
ues from those in isolated mitochondria but that the
main results of the studies on isolated mitochondria
remain, i.e. the control will be shared associated with
large threshold and large enzymatic reserve of most
of the steps in oxidative phosphorylation. The obser-
vation in the cases of mitochondrial mutations of the
necessity of a large degree of heteroplasmy of mutant
mtDNA (often higher than 90%) supports this pre-
diction.
Another prediction of metabolic control analysis
for the in vivo situation which should be similar to
what has been observed in isolated mitochondria is
that the control, the threshold and the enzymatic
reserves are certainly di¡erent from one tissue to
another, due to the di¡erent functions ensured by
their mitochondria, the di¡erent respiratory sub-
strates they use and the di¡erent steady state at
which they work.
In addition, as shown by Wisniewski et al., it can
be expected that in vivo part of the control will be
attached to the demand in ATP (control coe⁄cient
of 0.5 in their experiments [44]) and also to the sup-
ply of respiratory substrates (most of the time the
control coe⁄cient for the pyruvate carrier in isolated
mitochondria is around 0.2 [32]). Because the sum of
the control coe⁄cients is 1, this leaves few control
for oxidative phosphorylation complexes themselves.
Consequently the thresholds in vivo should be higher
than for isolated mitochondria and also the reserve
in oxidative phosphorylation complexes.
However, as stressed by Arnold and Kadenbach
[51] attention must be paid to a possible loss of es-
sential metabolites and to the absence of cytosolic
substrate and coenzyme environment in isolated mi-
tochondria.
2.3. Validity of MCA for analyzing the control of
oxidative phosphorylation
These predictions are only valid assuming that
MCA applies to describe the control of oxidative
phosphorylations. Three assumptions, which lie at
the basis of MCA development, may not be com-
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pletely ful¢lled in the case of oxidative phosphoryla-
tion.
The ¢rst one supposes that the enzymes catalyzing
each step of the network and the metabolites are all
free to interact. This is not true for mitochondria,
which realize a compartmentation of individual sets
of the network. For instance in the case of mtDNA
mutations, it is not known if all mitochondria uni-
formly contain the same number of mutant mtDNA,
and this is probably not the case, especially for the
high degrees of heteroplasmy. It is also known from
histo-enzymology patterns that the distribution of
mutant mtDNA is di¡erent in di¡erent cells of the
same tissue. These constraints will modify the expres-
sion of the complex de¢ciencies.
The second one supposes that the enzymes in
the network are independent of each other, i.e. do
not interact. The existence in some conditions of
supercomplexes of respiratory complexes has recently
been shown in yeast and in mammals [52,53]. In
these conditions the defect in one complex will pre-
vent the electron to proceed in all the pathways at-
tached to the de¢cient complex. The ‘apparent’ con-
trol coe⁄cients in these cases will be higher, the
threshold lower and the enzymatic reserve of any
complex participating to the supercomplex will ap-
pear lower.
The third one concerns the regulation of oxidative
phosphorylation complexes. For a long time, Kaden-
bach et al. [51] have demonstrated that cytochrome c
oxidase is regulated by intramitochondrial ATP, ac-
companied by a change of hyperbolic into sigmoidal
kinetics which can strongly inhibit the cytochrome c
oxidase activity, thus dramatically reducing the re-
serve in this complex. This situation, which is far
from the measurement on isolated mitochondria
(with state 3 reached via addition of ADP), can
well occur in vivo. More recently, [54], Kadenbach
et al. showed that cytochrome c oxidase could be
phosphorylated in a cAMP dependent manner and
dephosphorylated with a mitochondrial protein
phosphatase calcium dependently. The phosphorylat-
ed cytochrome c oxidase once more shows a sigmoi-
dal kinetic as a function of cytochrome c concentra-
tion, leading to complete inhibition of the activity at
low concentration of cytochrome c. Once more, one
must admit that this situation is not taken into ac-
count in measurements on isolated mitochondria in
which cytochrome c oxidase appears non-phosphor-
ylated.
Another criticism can be addressed to MCA. In
principle MCA only applies to small variations of
activities, which is not the case for the description
of threshold curves. In fact, MCA is the study of
sensitivity to perturbations of metabolic networks
in the linear neighbourhood of a steady state. The
dimension of this neighbourhood depends upon the
network and the rate function around the steady
state. It can be rather large; in fact the threshold
point indicates the limit of this neighbourhood. In
Fig. 3B for instance it is very clear that the decrease
of respiratory £ux is linear until the threshold (70%
of COX inhibition) which extends the validity do-
main of MCA rather far from the steady-state point
de¢ned by step activity = 100% and £ux = 100%.
2.4. What are mitochondria doing in the cell?
Finally, mitochondrial diseases question the very
cellular functions of mitochondria: if in a¡ected tis-
sues the £ux of ATP synthesis is unchanged, is ac-
tually ATP synthesis the main function of mitochon-
dria? As a matter of fact it appears that in many
tissues a great part of ATP can be synthesized by
glycolysis; this is the case in liver where, in some
conditions, 50% of ATP is synthesized by glycolysis
[55], and it is of course the case for rho0 cells. Thus,
the damaging e¡ect of complex de¢ciencies has to be
looked for elsewhere. Once more MCA gives us a
working hypothesis: if, for a complex activity
change, the £uxes remain unchanged it is not the
case for the intermediate metabolites, the variations
of which have precisely the role of maintaining the
steady state at the same level ; in the case of oxidative
phosphorylation it means that the redox centers up-
stream from the defect are more reduced and thus
are able to produce more free radicals, engaging the
mitochondria and the cell in a vicious circle amplify-
ing the free radical production linked to metabolic
defects. Preliminary indications are now reported
showing that this could well be the case. Thus even
a mild chronic impairment in a complex activity
could act as a starting point engaging the cell in
the vicious circle of free radicals damaging mitochon-
dria. This point was well demonstrated in the work
of Barrientos and Moraes [49]. In their examples of
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xenomitochondrial cybrids (human-apes) and of a
rotenone-induced model of complex I de¢ciency,
they showed a signi¢cant increase in free radical pro-
duction, which triggers an apoptotic program in con-
ditions where there is no decrease in ATP synthesis.
In another work, Esposito et al. [56] demonstrated
on mitochondria isolated from mice lacking the
heart/muscle isoform of adenine nucleotide translo-
cator (ANT1), that oxidative phosphorylation was
inhibited and that markedly increased amounts of
reactive oxygen species (ROS) were produced in skel-
etal muscle, heart and brain, consistently with ANT1
expression in these tissues. On the contrary liver mi-
tochondria, which express a di¡erent ANT isoform,
produced normal low levels of ROS. This increased
production of ROS in muscle and heart was associ-
ated with a strong increase in MnSOD (mitochondria
speci¢c) in muscle and no increase in heart mito-
chondria, leading to an increase in mtDNA rear-
rangements in the heart and not in muscle. This
work shows two things: ¢rst the role of ROS in
damaging mitochondria in conditions where oxida-
tive phosphorylation is inhibited; second a di¡eren-
tial tissue susceptibility to ROS due to their di¡erent
capacity to protect against free radicals.
3. Summary
In summary, MCA is probably too simple to ac-
count for the complexity of the expression of oxida-
tive phosphorylation mutations in mitochondrial dis-
eases. However, it a¡orded the way to understand
two particular features of this expression. First the
existence of a great threshold in the expression of the
amount of the defect on the £uxes associated with an
enzymatic reserve, which could or could not exist in
vivo (but the problem is now clearly set). Second the
existence of di¡erences in the expression of oxidative
phosphorylation defects in di¡erent tissues, empha-
sizing the di¡erences in mitochondria for di¡erent
tissues in their di¡erent structural properties and
functions.
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